



PATENT
Docket No.:LAY-006 CIA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Group Art Unit: 1632 Examiner: Baker, A.

Serial No. 09/494,088 Filed: January 28, 2000

In re Application of: McGrogan et al.

OCT 31 2002

TECH CENTER 1600/2900

For: Production and Use of Dopaminergic Cells to Treat Dopaminergic Deficiencies

STATEMENT UNDER 37 C.F.R. 3.73(b)

Director of Patents
Washington, D.C. 20231

Layton Bioscience, Inc., a corporation, Assignee, states that it is the assignee of the entire right, title, and interest of the above-entitled patent application. An assignment from the inventors of the patent application was recorded in the United States Patent and Trademark Office at Reel 012649, Frame 0765, for which a copy thereof is attached.

The undersigned, whose title is supplied below, is authorized to act on behalf of the assignee.

Dated: 10/28/02

Respectfully submitted,

By:

Annemarie Moseley
President and CEO
Layton Bioscience, Inc.



OCT 29 2002
PATENT & TRADEMARK OFFICE

RECEIVED

BSL

OCT 31 2002

TECH CENTER 1600 2900

1A4-006 C/H
Commissioner for Trademarks
Arlington, VA 22202-3513
www.uspto.gov

MAY 03, 2002

PTAS

SIERRA PATENT GROUP, LTD.
TINA BOUNDS
P.O. BOX 6149
STATELINE, NV 89449



102013090A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 02/27/2002

REEL/FRAME: 012649/0765

NUMBER OF PAGES: 2

BRIEF: ASSIGNMENT OF ASSIGNEE'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNEE:
MCGRGAN, MICHAEL

DOC DATE: 11/14/2001

ASSIGNEE:
SNABLE, GARY


DOC DATE: 11/16/2001

ASSIGNEE:
LAYTON BIOSCIENCE, INC.
709 EAST EVELYN AVENUE
SUNNYVALE, CALIFORNIA 94086

SERIAL NUMBER: 09494088
PATENT NUMBER:

FILING DATE: 01/28/2000
ISSUE DATE:

SEDLEY PYNE, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS



ASSIGNMENT

WHEREAS, we,

Michael McGrogan, a US citizen, residing at 1405 Cedar Street, San Carlos, CA 94070; and Gary Snable, a US citizen, residing at 105 Reservoir Drive, Atherton, CA 94027.

hereinafter referred to as Assignors, have invented a "PRODUCTION AND USE OF DOPAMINERGIC CELLS TO TREAT DOPAMINERGIC DEFICIENCIES" for which we have executed application papers for a U.S. Patent thereon; filed 01/28/00, having serial no. 09/494,088 and;

WHEREAS, Layton Bioscience, a California corporation, having a place of business at 709 East Evelyn Avenue, Sunnyvale, CA 94086, hereinafter referred to as Assignee, is desirous of acquiring the exclusive right, title and interest in and to said invention and in and to the Letters Patent to be granted and issued therefore in the United States of America and its territories and possessions, and all countries foreign thereto;

NOW, THEREFORE, for a valuable consideration, the receipt of which is hereby acknowledged, we, the Assignors, do sell, assign, transfer and set over unto said Assignee, its successors and assigns, the full and exclusive right, title and interest in and to said invention, and in and to any and all Letters Patent to be granted and issued therefor, not only for, to and in the United States of America, its territories and possessions, but also for, to and in all other countries including all priority rights under the International Convention; and we hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent to said Assignee, its successors and assigns, in accordance with this Assignment.

IN TESTIMONY WHEREOF, Assignors have hereunto signed their name to this assignment on the date indicated below.

Michael McGrogan 11/14/01
Michael McGrogan Date

Gary Snable 11/16/01
Gary Snable Date